The top 5 OncLive TV videos of the week.
Related to this article
Read a refresh of hematologic cancer FDA and global regulatory news from September 2026.
The FDA approved pirtobrutinib for untreated chronic lymphocytic leukemia, granted priority review to elinzanetant for breast cancer hot flashes, and more.
The FDA has approved pirtobrutinib for the treatment of adult patients with previously untreated CLL or SLL harboring no known 17p deletion.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Immunotherapy Regimen Studied by Mayo Clinic for Stage 3 Colon Cancer
2
Dr Berdeja on the Potential Role of CELMoDs in Multiple Myeloma Management
3
Dr Goetz on the Navigation of Oral SERDs and Targeted Therapy in Advanced Breast Cancer
4
The Next Wave: ADCs, Targeted Therapies, and Emerging Strategies in Ovarian Cancer
5